HEAD-TO-HEAD COMPARISON
Mounjaro vs WegovyTirzepatide vs Semaglutide
Verdict: Mounjaro (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.
Side-by-side comparison
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval | 2022 | 2021 |
| Indication | Type 2 diabetes glycemic control | Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity |
| Starting dose | Step 1 of 6 | Step 1 of 5 |
| Maintenance target | 15 mg/week | 2.4 mg/week |
| Titration length | ~21 weeks | ~17 weeks |
| Mean weight loss | ~15 to 20% mean (off-label / secondary endpoint) | ~14.9% mean at 68 weeks (STEP-1) |
| HbA1c reduction | 2.0 to 2.5 pp (SURPASS) | ~1.6 pp (off-label in T2D) |
| Cost (US list) | ~$1,000 / mo US list | ~$1,350 / mo US list |
| Insurance | T2D indication usually covered | Patchy for obesity indication |
Who should pick which
- Pick Mounjaro if the primary clinical goal is glycemic control in Type 2 diabetes; the FDA indication aligns and insurance coverage is more reliable.
- Pick Wegovy if the primary goal is weight management with an obesity-indicated label. Higher maintenance dose and stronger trial weight-loss data.
- Consider Mounjaro (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
Switching between the two
Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Open Tirzepatide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Mounjaro better than Wegovy?
Mounjaro (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Mounjaro to Wegovy?
Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Mounjaro produce more weight loss than Wegovy?
Mounjaro: ~15 to 20% mean (off-label / secondary endpoint). Wegovy: ~14.9% mean at 68 weeks (STEP-1). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Mounjaro priced differently from Wegovy?
Mounjaro costs ~$1,000 / mo US list; Wegovy costs ~$1,350 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Mounjaro or Wegovy?
Mounjaro is FDA-approved for Type 2 diabetes; Wegovy is not. For T2D-specific use, the labeled product is the appropriate clinical choice and is more likely to be covered by insurance.
Related
For research informational use only. Not medical advice. Mounjaro is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.